Navigation Links
Regency Therapeutics and Daiichi Sankyo Announce Launch and Commercial Availability of SPRIX® (ketorolac tromethamine) Nasal Spray
Date:5/17/2011

SHIRLEY, N.Y. and PARSIPPANY, N.J., May 17, 2011 /PRNewswire/ -- Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available. SPRIX® was approved by the U.S. Food and Drug Administration (FDA) in May 2010 for the short-term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level.

SPRIX® is a prescription intranasal formulation of the analgesic ketorolac tromethamine injection, a non-steroidal anti-inflammatory drug (NSAID). Ketorolac tromethamine injection is currently widely used in hospitals and was previously marketed in the U.S. as Toradol® by Roche Laboratories. More than 500 million injections have been administered in the U.S. since its introduction in 1990. With the launch of SPRIX®, this potent non-opioid pain reliever is now available in a convenient self-administered intranasal dosage form.

SPRIX® was developed by ROXRO PHARMA, Inc. ROXRO was acquired by Luitpold in December 2010. Luitpold Pharmaceuticals is a New York based U.S. subsidiary of Daiichi Sankyo Co., Ltd. (Corporate Headquarters: Tokyo, Japan).

SPRIX® is supplied in boxes containing five single-day nasal spray bottles. Each single-day nasal spray bottle is designed to administer precisely metered doses of 100 Microlitres (15.75 mg) of ketorolac tromethamine per spray and contains sufficient quantity to deliver eight sprays, for a total of 126 mg of ketorolac tromethamine. For adult patients < 65 years of age, the recommended dosage is 31.5 mg (one 15.75 mg spray in each nostril) every six to eight hours. For patients greater than or equal to 65 years of age, renally impaired patients, and patients less than 110 lbs, the recommended dosage is 15.75 mg (one 15.75 mg spray i
'/>"/>

SOURCE Luitpold Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
2. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
3. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
4. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
7. Echo Therapeutics Expands Into New Headquarters in Philadelphia
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
10. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
11. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... UNION CITY, Calif. , Nov. 21, 2014 /PRNewswire/ ... products company manufacturing point-of-care instruments and consumables for the ... lab services to the veterinary and research markets in ... the completion of a stock purchase agreement to acquire ... United Kingdom based distribution organization. The ...
(Date:11/21/2014)... 21, 2014 Clementia Pharmaceuticals, ... Agency (EMA) has granted Orphan Medicinal Product ... candidate, for the treatment of fibrodysplasia ossificans ... disabling genetic disease characterized by painful, recurrent ... new abnormal bone formation. This process, known ...
(Date:11/21/2014)... YORK , Nov. 20, 2014  Market research firm ... the "Year of The Buy, in the medical device ... for medical devices will produce just 3% growth this ... actions, including acquisitions of product lines and entrance by ... annual survey of medical devices, The Global Market ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... NEW YORK, Sept. 12, 2011 A revolutionary new ... other technology - - the VivoSight® Optical Coherence ... to dermatologists in the U.S. for the first time. ... skin surface instantly, providing additional information which will allow ...
... Sept. 12, 2011 Intarcia Therapeutics, Inc. announced ... ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) ... the 47th Annual Meeting of the European Association ...  All three presentations are scheduled for Wednesday, September ...
Cached Medicine Technology:Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 2Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 3Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 4Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 2Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 3Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 4
(Date:11/22/2014)... November 22, 2014 In order to provide ... promotion of cocktail party dresses. The business knows that a ... social occasions. , Now, the party dresses supplier’s ... 70% off. As the leading company in fashion industry, LunaDress ... outfit for every customer. So it always raises the professional ...
(Date:11/22/2014)... Domestic farmgate milk and dairy ... due to a fall in demand for ... amid the global financial crisis. However, these declines ... dairy manufacturers on the international scene. Strong growth ... growth, primarily due to supply constraints in some ...
(Date:11/22/2014)... has been a historical time for Angeldress.co.uk, an excellent wedding ... some renowned review websites. Recently, the company has added to ... of wonderful sexy wedding dresses to its website. At the ... to an 80% discount on any order over GBP 149. ... dress at Angeldress.co.uk, which has garnered a hard core of ...
(Date:11/22/2014)... The Sports Conflict Institute is pleased to ... team of conflict resolution professionals. Baroff comes to SCI as ... has over 30 years experience as an arbitrator, educator, and ... to connect with SCI and bring my conflict resolution skills ... with a complete sports focus,” says Baroff. , “Roy has ...
(Date:11/22/2014)... Washington, DC (PRWEB) November 22, 2014 ... its monthly Tech Report , which features the ... Sofastaii, a technology expert and reporter for NewsWatch, conducted ... can easily improve the flavor of your water. , ... are everywhere. It’s important that everything is done to ...
Breaking Medicine News(10 mins):Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2
... cent OBC quota in Central educational institutions, Union Health ... was a media creation // and that the ... ,'The resistance was all by the media,' Ramadoss ... had supported the government proposal, he said 'This is ...
... more likely to suffer from cancer and die from it, ... at Israel's //Haifa University suspect that cancers are most likely ... II. ,The researchers looked at the incidence and ... European origin - comparing those who emigrated from Europe before ...
... trying to reattach the foot of a four-year-old boy. The boy ... father // riding over him on a lawn mover. ... a lawn mower when the boy came up unexpectedly behind him. ... into reverse and accidentally ran over the boy's leg. It was ...
... women to donate their eggs for research as they ... // which they say would hopefully find new treatments ... disease. ,They want to extract embryonic stem ... patients with diabetes or neurodegenerative disease, according to Nature ...
... antibiotics for three days rather than the usual concept of ... of common pneumonia // . ,According to researchers ... antibiotic-resistant bacteria, ,Lead researcher Dr. Jan M Prins, ... in Amsterdam said,’The question is how long you should treat ...
... conducted by Dr Taraneh Dean of the University of Portsmouth and ... restricted // in their food intakes because their parents ... team found that found that 54 per cent of a sample ... their parents were convinced that such food items initiated ...
Cached Medicine News:Health News:Pneumonia Effectively Treated with Short-Term Antibiotic Course 2
... Parachute Tissue Anchor allows one step fixation of ... for arthroscopic knotless rotator cuff repair in one ... an outside thread diameter of 5 mm and ... FiberWire suspension sutures securely hold a thin, bioabsorbable ...
... The Bio-SutureTak is a 3 mm bioabsorbable ... ideal for soft tissue attachment to bone in ... small anchor profile with high pull-out strength is ... molded into the body of the anchor and ...
TigerStick is a white #2 FiberStick with black stripes and a stiffened, 12 inch, waxed end. It is especially useful when motion determination and alternating colored sutures are required in the arthr...
... MMS soon offers the Flowmaster. It is ... everyday flow studies, where ease of use, simplicity ... wireless uroflowmeter which makes it now very easy ... the flowmaster anywhere you want and data will ...
Medicine Products: